Writing About Deals, Acquisitions, and Market Moves Without Corporate Jargon

This guide is built for pharma, finance, and business editors who need to turn high-stakes announcements into readable, credible copy. It shows how to cover acquisition news, market moves, and deal-making with plain English, while preserving the nuance readers need to understand risk, scale, and business impact. If you want a broader editorial framework for turning messy data into usable narratives, you may also find From Stats to Stories useful for structure and sector dashboard thinking helpful for pattern recognition. The goal is simple: make your writing easier to read without making it easier to dismiss.

1) Why Corporate Jargon Creeps Into Deal Coverage

Press releases are optimized to sound broad, not clear

Corporate language tends to be self-protective. A company announcing an acquisition rarely wants to say “we paid a lot for a risky asset with uncertain upside,” even if that is closer to the truth. Instead, it leans on euphemisms such as “strategic fit,” “accelerating growth,” and “enhancing capabilities,” because these phrases sound positive while hiding the details. When you rewrite the announcement, your job is to keep the substance and remove the smoke.

This is especially important in pharma news, where the difference between “late-stage” and “mid-stage” can materially affect reader interpretation. In the source example, Lilly’s proposed purchase of Centessa was framed around sleep-wake disorders and mid-stage narcolepsy data; that is far more useful than repeating a generic “pipeline strengthening” phrase. Readers need to know the asset, the stage, the intended use, and the size of the bet. Those are the facts that let them judge whether the deal is bold, cautious, or overpriced.

Jargon is often a symptom of unclear thinking

Sometimes corporate jargon is deliberate, but often it is just lazy shorthand. Writers fall back on terms like “market moves” because they have not yet decided what the move means: Is it a defensive acquisition, a growth play, a portfolio cleanup, or a response to pressure? In business writing, clarity starts before sentence one. If you cannot define the move in plain language, the reader definitely cannot infer it from jargon.

One useful discipline is to write the simplest factual version of the event first. For example: “Biogen will buy Apellis for about $5.6 billion to expand in rare disease.” That sentence tells the reader who, what, why, and how much. Only after that should you add context, such as pipeline overlap, competitive positioning, or investor reaction. You can apply the same discipline in other sectors, whether you are reporting on aftermarket consolidation or writing about business features like enterprise customer implications.

Plain English builds trust faster than polish does

In deal coverage, trust matters because readers are often trying to make decisions under uncertainty. Investors want to know if a move changes valuation logic. Pharma professionals want to know if a licensing or acquisition strategy changes the pipeline. General business readers want to understand whether the announcement signals momentum, trouble, or noise. Clear writing helps all three groups move faster, and speed is a form of editorial value.

Pro Tip: If a sentence contains three abstract nouns in a row, stop and unpack it. “Commercial optimization initiatives” becomes “cuts costs and pushes sales faster.” That test alone removes a surprising amount of fluff.

2) How to Translate Deal Language Into Plain English

Replace abstractions with actions

The fastest way to remove corporate jargon is to swap abstract nouns for verbs. “The company is pursuing expansion through strategic acquisition” becomes “the company is buying a competitor to grow faster.” “It is unlocking synergies” becomes “it expects to save money by combining operations.” Verbs do not just improve readability; they restore agency and clarify cause and effect. Readers should never have to decode who is doing what to whom.

This translation approach is just as useful in finance news as it is in pharma news. When a market note says a company is “exposed to volatility,” ask what that exposure looks like: falling margins, higher input costs, lower patient demand, or slower deal flow. For a helpful model of turning numbers into a coherent business story, see five KPI tracking and market chart stack decision-making. Good reporting is not about replacing jargon with adjectives; it is about replacing it with concrete action.

Use the “what changed?” test

Every sentence in deal coverage should answer one of five questions: what changed, who is affected, why now, how big is it, and what happens next? If a sentence does not answer at least one, it may be filler. This is especially helpful in acquisition coverage, where announcements often contain repetitive paragraphs about “shared values” and “long-term potential” that say nothing about the actual transaction. When in doubt, pull the sentence back to reality.

For example, “Novo Nordisk launched a Wegovy subscription program for cash-pay patients” is clearer than “Novo Nordisk continues expanding access and affordability solutions.” The first sentence says what exists now. The second sentence sounds like strategy speak. The same principle appears in product and operations coverage, such as ad strategy changes or AI-powered learning design: readers want the visible change, not the slogan.

Define terms the first time you use them

Deal coverage often assumes shared knowledge that the reader may not have. Terms like EBITDA, pipeline, cash-pay, spinout, or accretion should be used carefully and explained when necessary. You do not need to define every financial term in every story, but you should explain the ones that carry the burden of interpretation. If you write for mixed audiences, assume competence but not context.

A strong pattern is to use the term and define it in the same sentence: “The company expects the deal to be accretive, meaning it could increase earnings per share after integration.” That is more useful than dropping the acronym and hoping the reader keeps up. This also helps in adjacent coverage like vendor stability or vendor negotiation, where readers may need operational context more than technical depth.

3) Writing Acquisition Coverage That Feels Accurate, Not Inflated

Lead with the transaction, not the trophy language

In acquisition coverage, the lead should tell readers the structure of the deal before anything else. Who bought whom? For how much? What does each side get? What strategic problem is this supposed to solve? A story that begins with “In a bold move to redefine the future…” makes readers work too hard. A story that begins with “Company A will buy Company B for $X billion to expand into Y” immediately earns attention because it is efficient and specific.

That discipline matters in pharma, where acquisitions can be framed as research bets, commercial expansion, or therapeutic diversification. The Lilly and Biogen examples from the source material are strong because they identify the target, the dollar value, and the therapeutic area. They also let a writer fairly discuss stage of development, portfolio fit, and likely integration challenges. If the story involves longer-form business outcomes, you can mirror the structure used in scaling and quality tradeoff pieces and context migration analyses, which similarly ask what changes after the handoff.

Separate announced intent from likely impact

Executives often describe a deal as immediately transformative. Editors should treat that claim as one opinion among several, not as a fact. The announcement is one thing; the impact is another. Your writing should distinguish between what the company says it plans, what analysts think it might achieve, and what evidence currently supports those claims.

For example, if a pharma company says an acquisition will strengthen its rare disease pipeline, the real reporting question is whether the acquired assets have clinical differentiation, regulatory momentum, or commercial potential. If the answer is weak, say so calmly. Readers respect precise skepticism more than blanket cynicism. This style is especially important when the market is volatile and companies are using acquisitions to signal confidence, much like how timing and signal interpretation matter in price pressure coverage or high-cost environment comparisons.

Keep valuation language measurable

When a deal is priced in billions, avoid vague words like “significant,” “substantial,” or “meaningful” unless you immediately explain what those terms mean in context. Is the premium large relative to the target’s last market price? Does the purchase price reflect a high-growth asset or a distressed one? Is the market reacting to the valuation or the strategy? These are the questions that give a deal story editorial weight.

A useful technique is to anchor valuation in one concrete comparison. You might say, “At about $6.3 billion, the deal is large enough to signal conviction, but not so large that it overwhelms the buyer’s balance sheet.” That sentence tells the reader something they can test. In finance and market writing, that kind of grounding often works better than sweeping claims, similar to how credit monitoring triggers and compensation comparisons translate opaque systems into readable decisions.

4) Pharma News: How to Stay Precise Without Sounding Like a Regulator

Use clinical stage language correctly

Pharma coverage falls apart when stage language gets sloppy. “Mid-stage” is not the same as “late-stage,” and “experimental” does not mean the same thing as “unproven.” Writers should know whether a therapy is in phase 1, phase 2, or phase 3, and what that means for confidence, timeline, and risk. If the therapy is aimed at narcolepsy or excessive daytime sleepiness, say that plainly rather than burying the indication under generic “neurology” language.

Readers do not need jargon; they need precision. When a company buys an asset in mid-stage studies, the correct editorial takeaway is that the science may be promising but still has substantial uncertainty. This is a different story from a purchase of an approved therapy with existing revenue. Coverage of vaccine, treatment, or public-health related business moves can also benefit from that same exactness, as seen in other medically adjacent coverage such as vaccine-related explanatory reporting and marketing-vs-medicine analysis.

Translate commercial strategy into reader consequences

Pharma executives often speak in terms of portfolio strategy, but readers care about downstream consequences. If a company buys a sleep-disorder asset, what does that mean for competition, patient access, R&D priorities, or sales force focus? If a drug is being sold via subscription for cash-pay patients, what does that suggest about affordability, channel strategy, or payer friction? Those are the meaningful translation targets.

Here, “plain English” does not mean oversimplified. It means writing at the level where a knowledgeable reader can quickly understand the business stakes. In the source example, Doctors Without Borders criticized Gilead’s refusal to sell more PrEP, which is not just a supply issue but also a story about access, ethics, and power. You can bring similar clarity to other complex systems by studying operational bottlenecks and risk migration coverage, where the real issue is how a change affects people on the ground.

Make drug access and pricing human

Whenever possible, write price and access in terms of actual use. “Eligible self-pay patients can access Wegovy through telehealth partners” is more concrete than “the company is improving affordability pathways.” The difference matters because the first sentence gives readers a workflow they can visualize: who can get it, through what channel, and at what monthly price. That is better journalism and better service.

When coverage includes pricing ladders, tiered plans, or subscription programs, consider whether the reader needs a simplified breakdown. A table or short bullet list can often replace three paragraphs of hedged prose. That visual clarity is common in good product comparison writing, from value comparisons to deal-versus-upgrade decisions, and the same logic works in pharmaceutical pricing coverage.

5) Finance and Market Moves: How to Sound Informed Without Puffery

Differentiate a move, a trend, and a signal

Finance writing often uses “market move” as a catchall phrase, but the word is too broad to be useful on its own. A move can be a stock reaction, a strategic acquisition, a policy shift, a sector rotation, or a change in guidance. The more precise you are, the more authority you project. Readers trust writers who know the difference between a one-day bounce and a durable trend.

For example, in a market correction, the meaningful question is not “are we recovering?” but “what is driving the rebound, and is it broad enough to matter?” That logic is similar to the framing in market-recovery commentary, where context beats hype. If the move is tied to a narrower set of leaders, say so. If it reflects changes in rates, sentiment, or liquidity, explain the mechanism in plain language.

Use cause-and-effect sentences

One of the best ways to eliminate jargon in finance coverage is to write in cause-and-effect form. “Higher borrowing costs are making acquisitions more expensive” is better than “the M&A environment remains challenging.” “Lower demand is slowing revenue growth” is better than “macro softness is pressuring the top line.” These sentences are shorter, but more importantly, they reveal the logic of the story.

This kind of writing helps readers understand market moves without forcing them to decode euphemisms. It also makes it easier to compare different industries. For instance, a business audience can use the same reasoning framework to think about market analysis for content planning, financial stability of vendors, or even strategy shifts in retail crypto adoption. Good explanation writing scales across sectors because the underlying logic is always the same.

Watch out for fake certainty

Corporate and financial language often tries to sound more certain than the evidence allows. Phrases like “clearly,” “inevitable,” “game-changing,” and “best-in-class” can make a story feel inflated. Strong editors know that confidence should come from evidence, not volume. If the numbers are uncertain, say so. If the deal thesis is still being tested, say that too.

That restraint does not weaken the piece; it strengthens it. Readers can tell the difference between a writer who is forcing a conclusion and one who is helping them reach it. In a crowded news environment, restraint is a competitive advantage. It makes your copy feel like analysis rather than repetition, much like how data-first decision making and open-source signal tracking improve strategic judgment.

6) A Practical Style System for Editorial Clarity

Build a reusable translation checklist

If you cover deals regularly, create a checklist for each story before drafting. Ask: What happened? Who paid? What changed strategically? What is the relevant timeline? What do readers need to understand about risk, valuation, and consequences? The checklist keeps your copy grounded and reduces the temptation to recycle corporate phrasing.

Another useful habit is to flag any sentence containing “enhance,” “optimize,” “leverage,” “unlock,” or “synergy,” then rewrite it in concrete terms. For example, “The merger will unlock efficiencies” becomes “the merger should cut duplicated costs.” “The acquisition will leverage scale” becomes “the buyer can spread fixed costs across more products.” These substitutions improve readability while preserving business meaning. That same editorial rigor helps in systems-oriented coverage like knowledge management and technical checklist writing.

Match tone to the outlet and audience

Plain English does not mean the same thing for every publication. A trade audience may tolerate more technical detail, but it still values clarity. A general business audience needs more explanation and fewer shorthand references. A financial audience may want model implications, while a pharma audience may want pipeline and regulatory context. Your style guide should define how much background to include and what terms always need explanation.

The strongest writing sounds authoritative because it is specific, not because it is inflated. That means choosing words that fit the level of certainty you actually have. If the deal has been announced but not closed, do not write as though it is already complete. If the market reaction is mixed, do not describe it as universally positive. Simple honesty is a style choice.

Use structure to carry the complexity

When the subject is dense, structure becomes part of the writing. Start with the transaction, follow with strategic context, then explain implications, risks, and next steps. Short paragraphs help the reader move through the story without losing orientation. Tables, subheads, and summary lines are not decoration; they are navigation tools.

That is why comparison writing works so well for deal coverage. A structured breakdown can show the difference between announced value, strategic purpose, clinical stage, market position, and potential risks in a single glance. This is the same logic behind practical comparison articles such as deal-finding analytics and